ClinicalTrials.gg
CompletedNCT05163886Updated Sep 29, 2026Results posted

Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis

A Phase 2 interventional study of LAM-002A and Placebo in Amyotrophic Lateral Sclerosis and ALS, sponsored by IRulya Therapeutics Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by IRulya Therapeutics Inc. · Phase 2, Interventional, and Treatment

How we know

Updated Sep 29, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Enrollment
225th of 307
15 · median 33
Started
2021
with 32 others
Phase 2
89 of 440
8 open now
Registered
311th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 225th largest by enrollment of the 307 interventional ones that give a count, is one of 33 that started in 2021, is one of 89 in phase 2, and was the 311th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This is a clinical trial to evaluate the safety, tolerability, and biological effect of LAM-002A in adults with C9ORF72-associated ALS (C9ALS).

Read the detailed description

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, biomarker-driven clinical trial evaluating the safety, tolerability, and biological effect of LAM-002A in approximately 12 adults with C9ORF72-associated ALS (C9ALS).

In Part A of the study, approximately twelve C9ALS participants will receive either standard of care plus LAM-002A or standard of care and placebo (randomized 2:1) for the first 12 weeks of the study (Core Study). LAM-002A will be administered as oral capsules 125 mg BID (250 mg total daily dose). The LAM-002A dose may be reduced to 100 mg BID (200 mg total daily dose) if expected gastrointestinal side effects develop.

Participants who complete the first 12 weeks of the Core Study will be eligible to receive active drug (LAM-002A capsules at maximum tolerated dose of 125 or 100 mg BID) for the remainder of the study (open-label extension [OLE]) up to Week 24.

In Part B of the study, participants who complete Part A Week 24 on study drug, will be offered the opportunity to opt-in to continue the open label extension for additional 36 weeks starting at the week 24 visit. Participants who elect not to roll over into the Treatment period B will complete the Day 168 visit, followed a final safety telephone call visit at week 28 to complete study participation. Participants who opt-in to the open label extension for an additional 36 weeks will have their end of study safety telephone call at week 64.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
  • ALS

Keywords

  • C9ORF72
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of C9ORF72-associated ALS with BOTH of the following:

    1. Documentation of a clinical genetic test demonstrating the presence of a pathogenic repeat expansion in C9ORF72. If there is a strong clinical suspicion for C9ALS based on C9-positive family history and El Escorial Criteria consistent with a diagnosis of ALS, clinical testing for the C9ORF72 repeat expansion may be performed with study screening labs at the discretion of the Site Investigator (SI), medical monitor, and study sponsor.

      AND

    2. Must meet possible, laboratory-supported probable, probable, or definite criteria for diagnosing ALS by revised El Escorial criteria (Brooks 2000).
  2. Age 18 or older
  3. Capable of providing at the Screening Visit and complying with study procedures throughout the study, in the SI's opinion, and at the discretion of the medical monitor and study sponsor.
  4. In the case that a participant lacks the ability to provide informed consent. Informed consent will be sought from the participant's surrogate representative.
  5. Able to safely swallow study drug capsule at screening and throughout study. May use thickened substances to assist in swallowing drug.
  6. Vital Capacity greater than and equal to 50% of predicted at the time of the Screening Visit measured by Slow Vital Capacity (SVC), or, if required due to COVID-19 pandemic-related restrictions and with Sponsor approval, Forced Vital Capacity (FVC) measured in-person or via telemedicine.
  7. Participants must either not take or be on a stable dose of riluzole (as either a tablet or oral suspension) for greater than 30 days prior to the Screening Visit. Riluzole-naïve participants are permitted in the study.
  8. Participants must either not take edaravone or have completed at least one 14-day cycle with plan for continuation of edaravone prior to the Screening Visit. Participants must be off cycle and at least 2 days after the last dose administration of edaravone at the time of study visit. Edaravone-naïve participants are permitted in the study.
  9. Participants must be able to complete all study procedures, including the lumbar punctures (LP) at the time of the Screening Visit, in the SI's opinion.
  10. Geographically accessible to the site.

Exclusion criteria

Exclusion Criteria:

  1. unstable medical condition (other than ALS) that would pose a risk to the participant, according to the SI's judgment [e.g., cardiovascular instability, systemic infection, or clinically significant laboratory abnormality or (ECG) changes].

    1. Gastrointestinal disease (e.g., gastric, or intestinal bypass surgery, jejunostomy tube, pancreatic enzyme insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic diarrheal illness, bowel obstruction) that might interfere with drug absorption or with interpretation of gastrointestinal AEs. Gastrostomy tube placement is allowed prophylactically or to supplement nutrition/hydration but may not be used for study drug administration.
    2. Hepatic profile showing any of the following:

    i. Serum (ALT) greater than 5 × (ULN).

    ii. Serum aspartate aminotransferase (AST) greater than 5 × ULN.

    iii. Serum greater than 1.5 × ULN.

    c. Renal profile showing an estimated (eClCR) less than 30 mL/minute (with eClCR to be calculated by the method at the laboratory performing the serum creatinine test).

  2. Presence of a neurodegenerative cognitive or motor syndrome (e.g., Alzheimer's disease, Parkinson's disease) not related to the C9ORF72 repeat expansion.
  3. Presence of unstable psychiatric disease or substance abuse that would impair ability of the participant to provide , in the SI's opinion.
  4. Active cancer or history of cancer, except for the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ, prostatic carcinoma in situ, or other curatively treated and with no evidence of disease recurrence for at least 3 years. Active cancer includes cancers with current disease manifestations or therapy that could adversely affect subject safety and longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.
  5. Prior solid organ transplantation.
  6. Ongoing therapy including systemic or enteric at screening or for the duration of the trial, at the discretion of the site investigator and medical monitor.
  7. Use within 5 days prior to randomization or for the duration of the trial of a strong inhibitor or inducer of cytochrome P450 (CYP) 3A4 or expected requirement for chronic use of a strong inhibitor or inducer of during study therapy.
  8. Use within 5 days prior to randomization or for the duration of the trial of drug that is a moderate-to-strong substrate of CYP2C9 (including warfarin, tolbutamide, phenytoin, glimepiride) or expected requirement for chronic use of such drugs during study therapy, at the discretion of the site investigator and medical monitor.
  9. Use of treatments for ALS (off-label use or active participation in a clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the Screening Visit.
  10. Exposure at any time to any gene therapies under investigation for the treatment of ALS (off-label use or investigational).
  11. If female, breastfeeding, known to be pregnant, planning to become pregnant during the study, or of and unwilling to use effective for the duration of the trial and for 3 months after discontinuing treatment.
  12. If male of reproductive capacity, unwilling to use effective contraception for the duration of the trial and for 3 months after discontinuing study treatment.
  13. Anything that would place the participant at increased risk or preclude the participant's full compliance with or completion of the study, in the SI's opinion.
  14. If a participant is being re-screened, the disqualifying condition has not been resolved, or the mandatory wash-out duration has not occurred.
  15. to undergoing a lumbar puncture (LP) in the SI's opinion. Participants undergoing the LP must not be currently taking anticoagulation and antiplatelet medications such as warfarin and clopidogrel bisulfate (Plavix™), that would be a contraindication to LP; aspirin and non-steroidal anti-inflammatories are allowed.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    LAM-002A

    LAM-002A will be administered orally in five 25 mg capsules twice a day (250 mg total daily dose).

    Drug: LAM-002A

  • Placebo comparator
    Placebo

    Placebo matching LAM-002A will be administered orally in 5 capsules twice a day.

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Safety of LAM-002A: Occurrence of TEAEs and SAEs

    Number of Participants with Treatment-Related Adverse Events (TEAEs) and Serious Adverse Events

    Time frame: 24 Weeks

  2. Tolerability of LAM-002A: Completion of Core Study Treatment

    The percentage of participants who complete 12 weeks on study treatment during the Core Study.

    Time frame: 12 Weeks

  3. Plasma Pharmacokinetics of LAM-002A and Major Metabolites

    The concentration of LAM-002A and its major metabolites (STA-5908, STA-5944, and STA-6048) in plasma.

    Time frame: 24 Weeks

  4. CSF Pharmacokinetics of LAM-002A and Major Metabolites

    The concentration of LAM-002A and its major metabolites (STA-5908, STA-5944, and STA-6048) cerebral spinal fluid (CSF).

    Time frame: 24 Weeks

Secondary outcomes

  1. Changes in Plasma Level of sGPNMB

    Changes in plasma levels of the LAM-002A-induced biomarker, soluble glycoprotein nonmetastatic melanoma protein B (sGPNMB)

    Time frame: 12 Weeks

  2. Changes in CSF Level of sGPNMB

    Changes in cerebrospinal fluid (CSF) levels of the LAM-002A-induced biomarker, soluble glycoprotein nonmetastatic melanoma protein B (sGPNMB)

    Time frame: 12 Weeks

  3. Tolerability of LAM-002A: Completion of Open-label Study Treatment

    Secondary measures of tolerability will consider completion of 12 weeks on open-label study treatment during the OLE through study Week 24.

    Time frame: 24 Weeks

Other outcomes

  1. Changes in ALSFRS-R Total Score and Domain Scores

    Change in Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) total and domain scores. The assessment consists of 12 everyday tasks, grouped into four main domains. Each task is scored from 0 (complete loss of function) to 4 (normal ability). The total score is the sum of the domain scores (bulbar: 0-12 points; fine motor: 0-12 points; gross motor: 0-12 points; respiratory: 0-12 points). The maximum total score is 48 points, with the higher the score indicating better function.

    Time frame: 24 Weeks

  2. Percent Predicted Slow Vital Capacity

    The percent predicted in slow vital capacity (SVC) over time. Predicted and Percent predicted values for slow vital capacity (SVC) were calculated using Quanjer Global Lung Initiative (GLI) equations based on participant age, sex, height at baseline, and self-reported race/ethnicity matched to GLI categories.

    Time frame: 24 Weeks

  3. Permanent Assisted Ventilation-free Survival

    Number of participants that required permanent-assisted-ventilation (or died)

    Time frame: 24 Weeks

  4. Changes in ALS-CBS

    Change in Amyotrophic Lateral Sclerosis Cognitive Behavioral Scale (ALS-CBS). Comprised of two sub-scores. The cognitive sub-score is rated 0-20 with the higher the score the better patient cognitive function. The behavioral sub-score was assessed by the caregiver and is rated 0-45 with the higher the score the better patient behavioral function.

    Time frame: 24 Weeks

  5. CSF Levels of NfL

    Changes in cerebrospinal fluid (CSF) levels of the exploratory disease related biomarker, neurofilament light chain (NfL). Decreases in NfL are considered positive pharmacological effects of LAM-002A.

    Time frame: 24 Weeks

  6. Plasma Levels of NfL

    Changes in plasma levels of the exploratory disease related biomarker, neurofilament light chain (NfL). Decreases in NfL are considered positive pharmacological effects of LAM-002A.

    Time frame: 12 Weeks

  7. CSF Levels of Poly (GP) Dipeptide Repeats

    Changes in cerebrospinal fluid (CSF) levels of the exploratory disease related biomarker, Poly(GP) dipeptide repeats. Decreases in poly (GP) are considered positive pharmacological effects of LAM-002A.

    Time frame: 24 Weeks

  8. PBMC Levels of Poly (GP) Dipeptide Repeats

    Changes in peripheral blood mononuclear cells (PBMC) levels of the exploratory disease related biomarker, Poly(GP) dipeptide repeats. Decreases in poly (GP) are considered positive pharmacological effects of LAM-002A.

    Time frame: 24 Weeks

07

Results

Posted Sep 29, 2026
Limitations and caveats
Part A (placebo-controlled through Week 12 and open label through Week 24) and B (open label extension) of the study was completed after all participants reached ≥24 weeks of study drug administration to allow the participants to begin treatment with Relyvrio, a drug that had recently been approved by the FDA. Participants still on study were eligible to be reconsented to Part C (open label extension) if they did not want to begin Relyviro treatment.

Participant flow

The study was conducted at four study centers who consented or screened at least one participant.

Part A (Weeks 1-24)
Participant flow — Part A (Weeks 1-24)
MilestoneLAM-002A Weeks 1-24 and OLE (Part B and Part C)Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C)
Started105
Completed treatment to week 1295
Completed treatment to week 2473
Completed83
Not completed22
Withdrew: Adverse event10
Withdrew: Death01
Withdrew: Progressive disease11
Part B
Participant flow — Part B
MilestoneLAM-002A Weeks 1-24 and OLE (Part B and Part C)Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C)
Started42
Completed00
Not completed42
Withdrew: Study terminated by sponsor42
Part C
Participant flow — Part C
MilestoneLAM-002A Weeks 1-24 and OLE (Part B and Part C)Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C)
Started31
Completed00
Not completed31
Withdrew: Death10
Withdrew: Disease progression21

Outcome measures

PrimarySafety of LAM-002A: Occurrence of TEAEs and SAEs

Number of Participants with Treatment-Related Adverse Events (TEAEs) and Serious Adverse Events

Time frame:
24 Weeks
Reported as:
Count of participants · Participants
Safety of LAM-002A: Occurrence of TEAEs and SAEs
ParticipantsLAM-002A Weeks 1-24Placebo Weeks 1-12LAM-002A Weeks 12-24
Treatment Emergent Adverse Events (TEAEs)1035
Serious Adverse Events (SAEs)101
PrimaryTolerability of LAM-002A: Completion of Core Study Treatment

The percentage of participants who complete 12 weeks on study treatment during the Core Study.

Time frame:
12 Weeks
Reported as:
Count of participants · Participants
Tolerability of LAM-002A: Completion of Core Study Treatment
ParticipantsLAM-002A Weeks 1-24Placebo Weeks 1-12
Tolerability of LAM-002A: Completion of Core Study Treatment95
PrimaryPlasma Pharmacokinetics of LAM-002A and Major Metabolites

The concentration of LAM-002A and its major metabolites (STA-5908, STA-5944, and STA-6048) in plasma.

Time frame:
24 Weeks
Reported as:
Mean · ng/mL
Plasma Pharmacokinetics of LAM-002A and Major Metabolites
ng/mLLAM-002A Weeks 1-24Placebo Weeks 1-12 and LAM-002A Weeks 12-24
LAM-002A Baseline (predose)0.10 ± 0.0000.10 ± 0.000
LAM-002A Week 2 (1 hour post dose)269.73 ± 196.3020.10 ± 0.000
LAM-002A Week 4 (1 hour post dose)213.80 ± 122.0410.10 ± 0.000
LAM-002A Week 8 (1 hour post dose)344.10 ± 184.7000.18 ± 0.173
LAM-002A Week 12 (1 hour post dose)283.13 ± 135.198172.64 ± 149.986
LAM-002A Week 24 (1 hour post dose)315.40 ± 131.386153.83 ± 118.791
STA-5908 Baseline (predose)0.10 ± 0.0000.10 ± 0.000
STA-5908 Week 2 (1 hour post dose)188.02 ± 136.4170.10 ± 0.000
STA-5908 Week 4 (1 hour post dose)175.47 ± 151.4790.10 ± 0.000
STA-5908 Week 8 (1 hour post dose)274.14 ± 159.7770.13 ± 0.075
STA-5908 Week 12 (1 hour post dose)214.93 ± 141.64998.34 ± 99.581
STA-5908 Week 24 (1 hour post dose)270.60 ± 124.025109.60 ± 94.667
STA-5944 Baseline (predose)0.10 ± 0.0000.10 ± 0.000
STA-5944 Week 2 (1 hour post dose)332.60 ± 219.0780.10 ± 0.000
STA-5944 Week 4 (1 hour post dose)335.49 ± 242.0040.10 ± 0.000
STA-5944 Week 8 (1 hour post dose)452.01 ± 286.6890.18 ± 0.170
STA-5944 Week 12 (1 hour post dose)391.81 ± 229.064205.12 ± 195.581
STA-5944 Week 24 (1 hour post dose)384.40 ± 202.858226.70 ± 173.966
STA-6048 Baseline (predose)0.10 ± 0.0000.10 ± 0.000
STA-6048 Week 2 (1 hour post dose)110.97 ± 89.9470.10 ± 0.000
STA-6048 Week 4 (1 hour post dose)116.36 ± 137.8760.10 ± 0.000
STA-6048 Week 8 (1 hour post dose)156.73 ± 99.3350.11 ± 0.018
STA-6048 Week 12 (1 hour post dose)118.83 ± 95.80356.60 ± 53.608
STA-6048 Week 24 (1 hour post dose)227.38 ± 151.57668.53 ± 48.920
PrimaryCSF Pharmacokinetics of LAM-002A and Major Metabolites

The concentration of LAM-002A and its major metabolites (STA-5908, STA-5944, and STA-6048) cerebral spinal fluid (CSF).

Time frame:
24 Weeks
Reported as:
Mean · ng/mL
CSF Pharmacokinetics of LAM-002A and Major Metabolites
ng/mLLAM-002A Weeks 1-24Placebo Weeks 1-12 and LAM-002A Weeks 12-24
LAM-002A Baseline (predose)0.01 ± 0.0000.01 ± 0.000
LAM-002A Week 4 (1 hour post dose)1.50 ± 0.9010.01 ± 0.000
LAM-002A Week 8 (1 hour post dose)1.96 ± 1.1590.01 ± 0.000
LAM-002A Week 12 (1 hour post dose)1.63 ± 0.9371.03 ± 1.024
LAM-002A Week 24 (1 hour post dose)2.58 ± 2.0001.81 ± 1.709
STA-5908 Baseline (predose)0.01 ± 0.0000.01 ± 0.000
STA-5908 Week 4 (1 hour post dose)1.39 ± 1.1340.01 ± 0.000
STA-5908 Week 8 (1 hour post dose)1.98 ± 1.4840.01 ± 0.000
STA-5908 Week 12 (1 hour post dose)1.56 ± 1.4840.55 ± 0.521
STA-5908 Week 24 (1 hour post dose)2.21 ± 1.3340.50 ± 0.478
STA-5944 Baseline (predose)0.01 ± 0.0000.01 ± 0.000
STA-5944 Week 4 (1 hour post dose)1.07 ± 0.9650.01 ± 0.000
STA-5944 Week 8 (1 hour post dose)1.61 ± 1.4990.01 ± 0.000
STA-5944 Week 12 (1 hour post dose)1.26 ± 1.2780.59 ± 0.603
STA-5944 Week 24 (1 hour post dose)1.57 ± 1.0010.47 ± 0.367
STA-6048 Baseline (predose)0.01 ± 0.0000.01 ± 0.000
STA-6048 Week 4 (1 hour post dose)0.23 ± 0.2500.01 ± 0.000
STA-6048 Week 8 (1 hour post dose)0.36 ± 0.2700.01 ± 0.000
STA-6048 Week 12 (1 hour post dose)0.22 ± 0.2510.02 ± 0.014
STA-6048 Week 24 (1 hour post dose)0.68 ± 0.5310.04 ± 0.029
SecondaryChanges in Plasma Level of sGPNMB

Changes in plasma levels of the LAM-002A-induced biomarker, soluble glycoprotein nonmetastatic melanoma protein B (sGPNMB)

Time frame:
12 Weeks
Reported as:
Mean · pg/mL
Changes in Plasma Level of sGPNMB
pg/mLLAM-002A Weeks 1-24Placebo Weeks 1-12 and LAM-002A Weeks 12-24
Baseline (pre-dose)17640.9 (13373.0 to 23270.7)18111.4 (12241.6 to 26795.9)
Week 2 (1 hour post dose)26431.5 (20037.0 to 34866.8)17638.7 (11922.1 to 26096.5)
Week 4 (1 hour post dose)29904.2 (22351.1 to 40009.6)17555.0 (11865.5 to 25972.7)
Week 8 (1 hour post dose)39358.2 (29632.4 to 52276.2)17961.8 (12140.4 to 26574.5)
Week 12 (1 hour post dose)40425.7 (30436.1 to 53694.0)17989.9 (12159.4 to 26616.2)
Statistical analysis
  • LAM-002A Weeks 1-24 vs Placebo Weeks 1-12 and LAM-002A Weeks 12-24 · t-test, 2 sided · p = <0.001 (P-value is for the treatment dependent difference in change from baseline to Week 12)
SecondaryChanges in CSF Level of sGPNMB

Changes in cerebrospinal fluid (CSF) levels of the LAM-002A-induced biomarker, soluble glycoprotein nonmetastatic melanoma protein B (sGPNMB)

Time frame:
12 Weeks
Reported as:
Mean · pg/mL
Changes in CSF Level of sGPNMB
pg/mLLAM-002A Weeks 1-24Placebo Weeks 1-12 and LAM-002A Weeks 12-24
Baseline (pre-dose)2012.0 (1716.1 to 2358.9)1698.6 (1356.4 to 2127.2)
Week 4 (1 hour post dose)1819.7 (1548.6 to 2138.1)1693.3 (1352.1 to 2120.5)
Week 8 (1 hour post dose)1871.1 (1592.4 to 2198.5)1758.6 (1404.3 to 2202.3)
Week 12 (1 hour post dose)1990.0 (1693.7 to 2338.3)1821.1 (1454.2 to 2280.6)
Statistical analysis
  • LAM-002A Weeks 1-24 vs Placebo Weeks 1-12 and LAM-002A Weeks 12-24 · t-test, 2 sided · p = 0.352
SecondaryTolerability of LAM-002A: Completion of Open-label Study Treatment

Secondary measures of tolerability will consider completion of 12 weeks on open-label study treatment during the OLE through study Week 24.

Time frame:
24 Weeks
Reported as:
Count of participants · Participants
Tolerability of LAM-002A: Completion of Open-label Study Treatment
ParticipantsLAM-002A Weeks 1-24Placebo Weeks 1-12 and LAM-002A Weeks 12-24
Tolerability of LAM-002A: Completion of Open-label Study Treatment73
Other pre-specifiedChanges in ALSFRS-R Total Score and Domain Scores

Change in Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) total and domain scores. The assessment consists of 12 everyday tasks, grouped into four main domains. Each task is scored from 0 (complete loss of function) to 4 (normal ability). The total score is the sum of the domain scores (bulbar: 0-12 points; fine motor: 0-12 points; gross motor: 0-12 points; respiratory: 0-12 points). The maximum total score is 48 points, with the higher the score indicating better function.

Time frame:
24 Weeks
Reported as:
Mean · score on a scale
Changes in ALSFRS-R Total Score and Domain Scores
score on a scaleLAM-002A Weeks 1-24Placebo Weeks 1-12 and LAM-002A Weeks 12-24
Baseline ALFRS-R Bulbar Domain Score10.3 ± 2.218.4 ± 4.51
Baseline ALFRS-R Fine Motor Domain Score9.6 ± 2.328.0 ± 3.39
Baseline ALFRS-R Gross Motor Domain Score9.5 ± 2.0710.0 ± 2.55
Baseline ALFRS-R Respiratory Domain Score11.2 ± 1.2311.6 ± 0.89
Baseline ALFRS-R Total Score40.6 ± 5.0238.0 ± 6.96
Week 4 ALFRS-R Bulbar Domain Score10.4 ± 2.178.2 ± 4.76
Week 4 ALFRS-R Fine Motor Domain Score9.1 ± 2.387.6 ± 3.78
Week 4 ALFRS-R Gross Motor Domain Score8.8 ± 1.999.4 ± 3.13
Week 4 ALFRS-R Respiratory Domain Score11.4 ± 0.7011.2 ± 0.84
Week 4 ALFRS-R Total Score39.7 ± 4.8536.4 ± 9.13
Week 8 ALFRS-R Bulbar Domain Score10.1 ± 3.188.2 ± 4.76
Week 8 ALFRS-R Fine Motor Domain Score8.4 ± 2.077.6 ± 3.65
Week 8 ALFRS-R Gross Motor Domain Score7.9 ± 2.629.0 ± 3.24
Week 8 ALFRS-R Respiratory Domain Score11.4 ± 0.5310.8 ± 1.64
Week 8 ALFRS-R Total Score37.9 ± 6.4935.6 ± 9.91
Week 12 ALFRS-R Bulbar Domain Score9.7 ± 3.048.2 ± 4.76
Week 12 ALFRS-R Fine Motor Domain Score8.1 ± 2.807.0 ± 3.67
Week 12 ALFRS-R Gross Motor Domain Score7.6 ± 2.308.8 ± 3.63
Week 12 ALFRS-R Respiratory Domain Score11.0 ± 1.6610.6 ± 1.95
Week 12 ALFRS-R Total Score36.3 ± 6.7834.6 ± 9.02
Week 24 ALFRS-R Bulbar Domain Score9.1 ± 3.528.7 ± 4.93
Week 24 ALFRS-R Fine Motor Domain Score7.6 ± 2.885.0 ± 3.61
Week 24 ALFRS-R Gross Motor Domain Score6.0 ± 1.207.0 ± 2.00
Week 24 ALFRS-R Respiratory Domain Score11.0 ± 1.2011.7 ± 0.58
Week 24 ALFRS-R Total Score33.8 ± 6.9232.3 ± 10.69
Other pre-specifiedPercent Predicted Slow Vital Capacity

The percent predicted in slow vital capacity (SVC) over time. Predicted and Percent predicted values for slow vital capacity (SVC) were calculated using Quanjer Global Lung Initiative (GLI) equations based on participant age, sex, height at baseline, and self-reported race/ethnicity matched to GLI categories.

Time frame:
24 Weeks
Reported as:
Mean · percentage of predicted SVC
Percent Predicted Slow Vital Capacity
percentage of predicted SVCLAM-002A Weeks 1-24Placebo Weeks 1-12 and LAM-002A Weeks 12-24
Baseline78.0 ± 17.4676.7 ± 15.83
Week 481.6 ± 14.5866.9 ± 22.05
Week 881.6 ± 14.5868.5 ± 22.00
Week 1281.6 ± 14.5864.3 ± 24.95
Week 2475.1 ± 18.0659.4 ± 17.95
Other pre-specifiedPermanent Assisted Ventilation-free Survival

Number of participants that required permanent-assisted-ventilation (or died)

Time frame:
24 Weeks
Reported as:
Count of participants · Participants
Permanent Assisted Ventilation-free Survival
ParticipantsLAM-002A Weeks 1-24Placebo Weeks 1-12 and LAM-002A Weeks 12-24
Permanent Assisted Ventilation-free Survival01
Other pre-specifiedChanges in ALS-CBS

Change in Amyotrophic Lateral Sclerosis Cognitive Behavioral Scale (ALS-CBS). Comprised of two sub-scores. The cognitive sub-score is rated 0-20 with the higher the score the better patient cognitive function. The behavioral sub-score was assessed by the caregiver and is rated 0-45 with the higher the score the better patient behavioral function.

Time frame:
24 Weeks
Reported as:
Mean · score on a scale
Changes in ALS-CBS
score on a scaleLAM-002A Weeks 1-24Placebo Weeks 1-12 and LAM-002A Weeks 12-24
Cognitive Scale Baseline16.8 ± 2.7417.4 ± 1.14
Cognitive Scale Week 815.8 ± 3.4618.0 ± 1.83
Cognitive Scale Week 1215.9 ± 2.5217.4 ± 1.34
Cognitive Scale Week 2416.6 ± 2.5719.0 ± 1.00
Behavioral Scale Baseline40.0 ± 7.2644.0 ± 1.00
Behavioral Scale Week 839.8 ± 3.7642.0 ± 3.00
Behavioral Scale Week 1240.7 ± 3.0839.8 ± 5.68
Behavioral Scale Week 2440.3 ± 0.5838.0 ± 5.66
Other pre-specifiedCSF Levels of NfL

Changes in cerebrospinal fluid (CSF) levels of the exploratory disease related biomarker, neurofilament light chain (NfL). Decreases in NfL are considered positive pharmacological effects of LAM-002A.

Time frame:
24 Weeks
Reported as:
Mean · pg/mL
CSF Levels of NfL
pg/mLLAM-002A Weeks 1-24Placebo Weeks 1-12 and LAM-002A Weeks 12-24
Baseline (pre-dose)6706.826 ± 5697.38186301.775 ± 4539.1300
Week 4 (1 hour post dose)6106.606 ± 3807.72906121.476 ± 2207.9686
Week 8 (1 hour post dose)5979.763 ± 3021.30394915.784 ± 2286.8341
Week 12 (1 hour post dose)6372.683 ± 3606.46546875.761 ± 3260.2480
Week 24 (1 hour post dose)10041.440 ± 7355.13332932.091 ± 227.6043
Other pre-specifiedPlasma Levels of NfL

Changes in plasma levels of the exploratory disease related biomarker, neurofilament light chain (NfL). Decreases in NfL are considered positive pharmacological effects of LAM-002A.

Time frame:
12 Weeks
Reported as:
Median · pg/mL
Plasma Levels of NfL
pg/mLLAM-002A Weeks 1-24Placebo Weeks 1-12 and LAM-002A Weeks 12-24
Baseline (pre-dose)102 (20.4 to 140)71.9 (54.8 to 181)
Week 2 (1 hour post dose)108 (33.1 to 265)79.9 (56.2 to 188)
Week 4 (1 hour post dose)108 (33.1 to 265)76.6 (54.8 to 210)
Week 8 (1 hour post dose)132 (44.9 to 227)58.1 (53.0 to 230)
Week 12 (1 hour post dose)142 (42.5 to 211)62.0 (49.2 to 251)
Other pre-specifiedCSF Levels of Poly (GP) Dipeptide Repeats

Changes in cerebrospinal fluid (CSF) levels of the exploratory disease related biomarker, Poly(GP) dipeptide repeats. Decreases in poly (GP) are considered positive pharmacological effects of LAM-002A.

Time frame:
24 Weeks
Reported as:
Mean · Dipeptide Repeats
CSF Levels of Poly (GP) Dipeptide Repeats
Dipeptide RepeatsLAM-002A Weeks 1-24Placebo Weeks 1-12 and LAM-002A Weeks 12-24
Baseline436.99 ± 360.750851.80 ± 502.302
Week 4174.38 ± 172.814694.04 ± 339.209
Week 8148.40 ± 118.061690.17 ± 434.694
Week 12111.77 ± 96.820699.98 ± 281.230
Week 24161.04 ± 167.306407.10 ± 400.276
Other pre-specifiedPBMC Levels of Poly (GP) Dipeptide Repeats

Changes in peripheral blood mononuclear cells (PBMC) levels of the exploratory disease related biomarker, Poly(GP) dipeptide repeats. Decreases in poly (GP) are considered positive pharmacological effects of LAM-002A.

Time frame:
24 Weeks
Reported as:
Mean · Dipeptide Repeats
PBMC Levels of Poly (GP) Dipeptide Repeats
Dipeptide RepeatsLAM-002A Weeks 1-24Placebo Weeks 1-12 and LAM-002A Weeks 12-24
Baseline236.80 ± 158.286272.45 ± 89.363
Week 4183.97 ± 93.514274.75 ± 253.200
Week 8254.92 ± 209.838400.75 ± 270.411
Week 12225.14 ± 138.802260.75 ± 182.497
Week 2495.55 ± 73.369275.75 ± 197.283

Adverse events

Collected over From Baseline through Week 24. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LAM-002A Weeks 1-240/10 (0%)1/10 (10%)10/10 (100%)
Placebo Weeks 1-120/5 (0%)0/5 (0%)3/5 (60%)
LAM-002A Weeks 12-241/5 (20%)1/5 (20%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventLAM-002A Weeks 1-24Placebo Weeks 1-12LAM-002A Weeks 12-24
Respiratory failureRespiratory, thoracic and mediastinal disorders0/100/51/5
PancreatitisGastrointestinal disorders1/100/50/5
Most frequent other events
Showing 10 of 69
Most frequent other events
EventLAM-002A Weeks 1-24Placebo Weeks 1-12LAM-002A Weeks 12-24
FallInjury, poisoning and procedural complications6/102/51/5
DiarrhoeaGastrointestinal disorders4/100/51/5
NauseaGastrointestinal disorders4/100/50/5
ContusionInjury, poisoning and procedural complications4/100/50/5
COVID-19Infections and infestations4/100/51/5
HeadacheNervous system disorders4/101/50/5
ConstipationGastrointestinal disorders3/100/50/5
Procedural painInjury, poisoning and procedural complications3/100/50/5
Decreased appetiteMetabolism and nutrition disorders3/100/50/5
VomitingGastrointestinal disorders2/100/51/5

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)LAM-002A Weeks 1-24 and OLE (Part B and Part C)Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C)Total
<=18 years000
Between 18 and 65 years7512
>=65 years303
Age, Continuous
Age, Continuous(Years)LAM-002A Weeks 1-24 and OLE (Part B and Part C)Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C)Total
Mean62.3 ± 5.5060.0 ± 2.7461.5 ± 4.78
Sex: Female, Male
Sex: Female, Male(Participants)LAM-002A Weeks 1-24 and OLE (Part B and Part C)Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C)Total
Female516
Male549
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LAM-002A Weeks 1-24 and OLE (Part B and Part C)Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White10515
More than one race000
Unknown or Not Reported000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LAM-002A Weeks 1-24 and OLE (Part B and Part C)Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C)Total
Hispanic or Latino000
Not Hispanic or Latino10515
Unknown or Not Reported000
Weight
Weight(kg)LAM-002A Weeks 1-24 and OLE (Part B and Part C)Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C)Total
Mean74.04 ± 14.41472.54 ± 9.48673.54 ± 12.641
Height
Height(cm)LAM-002A Weeks 1-24 and OLE (Part B and Part C)Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C)Total
Mean173.06 ± 10.268173.46 ± 9.698173.21 ± 9.688
BMI
BMI(kg/m2)LAM-002A Weeks 1-24 and OLE (Part B and Part C)Placebo Weeks 1-12 and LAM-002A Weeks 12-24 and OLE (Part B and Part C)Total
Mean25.59 ± 3.65624.18 ± 3.31525.09 ± 3.478

1 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Johns Hopkins University School of Medicine
    Baltimore, Maryland 21205, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

References and documents

Publications

  • Babu S, Nicholson KA, Rothstein JD, Swenson A, Sampognaro PJ, Pant P, Macklin EA, Spruill S, Paganoni S, Gendron TF, Prudencio M, Petrucelli L, Nix D, Landrette S, Nkrumah E, Fandrick K, Edwards J, Young PR. Apilimod dimesylate in C9orf72 amyotrophic lateral sclerosis: a randomized phase 2a clinical trial. Brain. 2024 Sep 3;147(9):2998-3008. doi: 10.1093/brain/awae109. PubMed 38606777 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Jan 2023, 12 months.

Results were first posted in Sep 2026, 3 years 8 months after primary completion.

Of 36 industry-sponsored phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 12 months is below that.

Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2021
First posted
Dec 20, 2021
StartActual
Dec 23, 2021
Primary completionActual
Jan 11, 2023
CompletionActual
May 31, 2025
Results first posted
Sep 29, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Sep 29, 2026
Enrollment
14→15
Sep 29, 2026
Primary outcomes
4 edited
What changed in the outcomes
  • EditedSafety of LAM-002A: occurrenceOccurrence of TEAEs and SAEsTime frame: 28 Weeks → 24 Weeks
  • EditedTolerability of LAM-002A: completionCompletion of core study treatmentCore Study TreatmentTime frame: 12 Weeks
  • EditedPlasma Pharmacokinetics of LAM-002A and Major MetabolitesTime frame: 24 Weeks
  • EditedCSF Pharmacokinetics of LAM-002A and Major MetabolitesTime frame: 24 Weeks
Sep 29, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 38606777 ↗
Sep 29, 2026
Secondary outcomes
3 edited, 7 added, 3 removed, 1 description edited
What changed in the outcomes
  • EditedTolerability of LAM-002A: completionCompletion of openOpen-label study treatmentStudy TreatmentTime frame: 12 Weeks → 24 Weeks
  • AddedChanges in Plasma Level of sGPNMBTime frame: 12 Weeks
  • AddedChanges in CSF Level of sGPNMBTime frame: 12 Weeks
  • RemovedChanges in biomarkersTime frame: 24 Weeks
  • Editedother outcomeChanges in ALSFRS-R Total Score and Domain ScoresTime frame: 28 Weeks → 24 Weeks
  • Editedother outcomePermanent assisted ventilationAssisted Ventilation-free survivalSurvivalTime frame: 24 Weeks
  • Addedother outcomePercent Predicted Slow Vital CapacityTime frame: 24 Weeks
  • Addedother outcomeCSF Levels of NfLTime frame: 24 Weeks
  • Addedother outcomePlasma Levels of NfLTime frame: 12 Weeks
  • Addedother outcomeCSF Levels of Poly (GP) Dipeptide RepeatsTime frame: 24 Weeks
  • Addedother outcomePBMC Levels of Poly (GP) Dipeptide RepeatsTime frame: 24 Weeks
  • Removedother outcomeChanges in Vital CapacityTime frame: 24 Weeks
  • Removedother outcomeExploratory biomarkersTime frame: 24 Weeks
  • Descriptionother outcomeChanges in ALS-CBS: how it is measured was reworded
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 38606777 ↗
    Enrollment 14→15
    Primary outcomes 4 edited
    What changed in the outcomes
    • EditedSafety of LAM-002A: occurrenceOccurrence of TEAEs and SAEsTime frame: 28 Weeks → 24 Weeks
    • EditedTolerability of LAM-002A: completionCompletion of core study treatmentCore Study TreatmentTime frame: 12 Weeks
    • EditedPlasma Pharmacokinetics of LAM-002A and Major MetabolitesTime frame: 24 Weeks
    • EditedCSF Pharmacokinetics of LAM-002A and Major MetabolitesTime frame: 24 Weeks
    Secondary outcomes 3 edited, 7 added, 3 removed, 1 description edited
    What changed in the outcomes
    • EditedTolerability of LAM-002A: completionCompletion of openOpen-label study treatmentStudy TreatmentTime frame: 12 Weeks → 24 Weeks
    • AddedChanges in Plasma Level of sGPNMBTime frame: 12 Weeks
    • AddedChanges in CSF Level of sGPNMBTime frame: 12 Weeks
    • RemovedChanges in biomarkersTime frame: 24 Weeks
    • Editedother outcomeChanges in ALSFRS-R Total Score and Domain ScoresTime frame: 28 Weeks → 24 Weeks
    • Editedother outcomePermanent assisted ventilationAssisted Ventilation-free survivalSurvivalTime frame: 24 Weeks
    • Addedother outcomePercent Predicted Slow Vital CapacityTime frame: 24 Weeks
    • Addedother outcomeCSF Levels of NfLTime frame: 24 Weeks
    • Addedother outcomePlasma Levels of NfLTime frame: 12 Weeks
    • Addedother outcomeCSF Levels of Poly (GP) Dipeptide RepeatsTime frame: 24 Weeks
    • Addedother outcomePBMC Levels of Poly (GP) Dipeptide RepeatsTime frame: 24 Weeks
    • Removedother outcomeChanges in Vital CapacityTime frame: 24 Weeks
    • Removedother outcomeExploratory biomarkersTime frame: 24 Weeks
    • Descriptionother outcomeChanges in ALS-CBS: how it is measured was reworded
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05163886
Lead sponsor
IRulya Therapeutics Inc.
Responsible party
Sponsor
First posted
Dec 20, 2021
Start date
Dec 23, 2021
Primary completion
Jan 11, 2023
Completion
May 31, 2025
Results posted
Sep 29, 2026
Last update
Sep 29, 2026

Study contacts

Suma Babu, M.D.
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apilimod Dimesylate Capsule

Start the discussion